Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.05. | Protagenic Therapeutics sammelt 3,1 Millionen US-Dollar durch Optionsscheine ein | 2 | Investing.com Deutsch | ||
21.05. | Protagenic Therapeutics raises $3.1 million from warrants | 2 | Investing.com | ||
21.05. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity | 247 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have... ► Artikel lesen | |
20.05. | Pre-market Movers: Eyenovia, Instil Bio, Protagenic Therapeutics, Bon Natural Life, D-Wave Quantum | 592 | AFX News | BEIJING (dpa-AFX) - Pre-market Movers: EYEN, TIL, PTIX, BON, QBTS.The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Eyenovia... ► Artikel lesen | |
19.05. | Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher | 4 | Benzinga.com | ||
19.05. | Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger | 5 | Benzinga.com | ||
PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
19.05. | Protagenic Therapeutics Aktie steigt nach Fusion zur Gründung eines neuroaktiven Pharmaunternehmens | 7 | Investing.com Deutsch | ||
19.05. | Protagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical company | 1 | Investing.com | ||
19.05. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
19.05. | Protagenic Therapeutics merges with Phytanix Bio in all-stock deal | 3 | Investing.com | ||
19.05. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders | 326 | ACCESS Newswire | NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange... ► Artikel lesen | |
13.05. | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | 1 | SEC Filings | ||
05.05. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 3 | SEC Filings | ||
29.04. | Protagenic Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:14 an | 2 | Investing.com Deutsch | ||
29.04. | Protagenic Therapeutics announces 1-for-14 reverse stock split | 1 | Investing.com | ||
29.04. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split | 285 | ACCESS Newswire | Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics"... ► Artikel lesen | |
18.04. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | Protagenic Therapeutics, Inc.\new - 10-K, Annual Report | 3 | SEC Filings | ||
24.02. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
29.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,848 | +0,46 % | BioNTech SE: BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an | Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der... ► Artikel lesen | |
VALNEVA | 2,630 | +0,15 % | Valneva Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
BIOFRONTERA | 2,400 | -1,23 % | Biofrontera AG verhandelt über grundlegende Änderungen ihrer Zusammenarbeit mit der Biofrontera Inc. | Bad Marienberg (www.anleihencheck.de) - Die Biofrontera AG (ISIN DE000A4BGGM7/ WKN A4BGGM) steht mit der Biofrontera Inc. in Verhandlungen über eine weitere Anpassung des zwischen den beiden Gesellschaften... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,095 | 0,00 % | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,580 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,760 | +1,15 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,992 | +0,98 % | Ocugen To Present at BIO International Convention 2025 | ||
SANGAMO THERAPEUTICS | 0,418 | -0,41 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,655 | +0,35 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 0,970 | -3,96 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
EDITAS MEDICINE | 1,692 | -0,56 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,500 | -0,79 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,615 | +0,24 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen |